Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment

Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enh...

Full description

Bibliographic Details
Main Authors: Choi, Catherine H. (Author), Schoenfeld, Brian P. (Author), Bell, Aaron J. (Author), Hinchey, Paul (Author), Kollaros, Maria (Author), Gertner, Michael J. (Author), Woo, Newton H. (Author), Tranfaglia, Michael R. (Author), Zukin, R. Suzanne (Author), McDonald, Thomas V. (Author), Jongens, Thomas A. (Author), McBride, Sean M.J (Author), Bear, Mark (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences (Contributor), Picower Institute for Learning and Memory (Contributor)
Format: Article
Language:English
Published: Elsevier, 2016-04-15T15:18:17Z.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items